NMS·Healthcare·$199M·#134 / 520 in Healthcare
RNA Atrium Therapeutics, Inc.
60SOLID
CATEGORY BREAKDOWN
GROWTH88
QUALITY0
STABILITY100
VALUATION43
GOVERNANCE56
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+70.9%
88
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
79 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
1.8%
99
< 25% strong
Price / Sales
Market cap relative to trailing revenue
10.7x
43
< 3x strong
Rule of 40
Growth rate plus operating margin
-342
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.3%
34
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+0.0%
100
< 5% ideal
RELATED STOCKS
COMPARE RNA WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when RNA's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.